Royalty Pharma officer proposes $236K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc officer Marshall Urist reported a proposed sale of 4,126 shares, with an aggregate market value of $235,594.60, through Merrill Lynch; the approximate sale date is October 5, 2026. The shares are identified as Class A ordinary shares from an equity performance award granted August 7, 2026. Urist also reported sales of 9,099 shares on July 1, 2026, for $508,453.82, and 4,126 shares on September 28, 2026, for $238,812.88.
Key Figures
Key Terms
Rule 144 regulatory
Equity Performance Award financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.